Neurotrophic factor delivery as a protective treatment for glaucoma

Thomas Johnson, Natalie D. Bull, Keith R. Martin

Research output: Contribution to journalArticle

Abstract

Glaucoma is a progressive optic neuropathy and a major cause of visual impairment worldwide. Neuroprotective therapies for glaucoma aim to ameliorate retinal ganglion cell degeneration through direct or indirect action on these neurons. Neurotrophic factor (NTF) delivery is a key target for the development of potential neuroprotective glaucoma treatments. This article will critically summarize the evidence that NTF deprivation and/or dysfunction plays a role in the pathogenesis of glaucoma. Experimental support for the neuroprotective potential of NTF supplementation in animal models of glaucoma will be reviewed, in particular for brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Finally, the challenges of clinical translation will be considered with an emphasis on the most promising NTF delivery strategies including slow-release drug delivery, gene therapy, and cell transplantation.

Original languageEnglish (US)
Pages (from-to)196-203
Number of pages8
JournalExperimental Eye Research
Volume93
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Nerve Growth Factors
Glaucoma
Ciliary Neurotrophic Factor
Glial Cell Line-Derived Neurotrophic Factor
Therapeutics
Optic Nerve Diseases
Retinal Ganglion Cells
Vision Disorders
Brain-Derived Neurotrophic Factor
Cell Transplantation
Genetic Therapy
Animal Models
Neurons

Keywords

  • Cell transplantation
  • Gene therapy
  • Glaucoma
  • Neuroprotection
  • Neurotrophic factor
  • Neurotrophin
  • Slow release

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Neurotrophic factor delivery as a protective treatment for glaucoma. / Johnson, Thomas; Bull, Natalie D.; Martin, Keith R.

In: Experimental Eye Research, Vol. 93, No. 2, 01.08.2011, p. 196-203.

Research output: Contribution to journalArticle

Johnson, Thomas ; Bull, Natalie D. ; Martin, Keith R. / Neurotrophic factor delivery as a protective treatment for glaucoma. In: Experimental Eye Research. 2011 ; Vol. 93, No. 2. pp. 196-203.
@article{ab682c0fab944348a178353056c27de0,
title = "Neurotrophic factor delivery as a protective treatment for glaucoma",
abstract = "Glaucoma is a progressive optic neuropathy and a major cause of visual impairment worldwide. Neuroprotective therapies for glaucoma aim to ameliorate retinal ganglion cell degeneration through direct or indirect action on these neurons. Neurotrophic factor (NTF) delivery is a key target for the development of potential neuroprotective glaucoma treatments. This article will critically summarize the evidence that NTF deprivation and/or dysfunction plays a role in the pathogenesis of glaucoma. Experimental support for the neuroprotective potential of NTF supplementation in animal models of glaucoma will be reviewed, in particular for brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Finally, the challenges of clinical translation will be considered with an emphasis on the most promising NTF delivery strategies including slow-release drug delivery, gene therapy, and cell transplantation.",
keywords = "Cell transplantation, Gene therapy, Glaucoma, Neuroprotection, Neurotrophic factor, Neurotrophin, Slow release",
author = "Thomas Johnson and Bull, {Natalie D.} and Martin, {Keith R.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.exer.2010.05.016",
language = "English (US)",
volume = "93",
pages = "196--203",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Neurotrophic factor delivery as a protective treatment for glaucoma

AU - Johnson, Thomas

AU - Bull, Natalie D.

AU - Martin, Keith R.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Glaucoma is a progressive optic neuropathy and a major cause of visual impairment worldwide. Neuroprotective therapies for glaucoma aim to ameliorate retinal ganglion cell degeneration through direct or indirect action on these neurons. Neurotrophic factor (NTF) delivery is a key target for the development of potential neuroprotective glaucoma treatments. This article will critically summarize the evidence that NTF deprivation and/or dysfunction plays a role in the pathogenesis of glaucoma. Experimental support for the neuroprotective potential of NTF supplementation in animal models of glaucoma will be reviewed, in particular for brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Finally, the challenges of clinical translation will be considered with an emphasis on the most promising NTF delivery strategies including slow-release drug delivery, gene therapy, and cell transplantation.

AB - Glaucoma is a progressive optic neuropathy and a major cause of visual impairment worldwide. Neuroprotective therapies for glaucoma aim to ameliorate retinal ganglion cell degeneration through direct or indirect action on these neurons. Neurotrophic factor (NTF) delivery is a key target for the development of potential neuroprotective glaucoma treatments. This article will critically summarize the evidence that NTF deprivation and/or dysfunction plays a role in the pathogenesis of glaucoma. Experimental support for the neuroprotective potential of NTF supplementation in animal models of glaucoma will be reviewed, in particular for brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Finally, the challenges of clinical translation will be considered with an emphasis on the most promising NTF delivery strategies including slow-release drug delivery, gene therapy, and cell transplantation.

KW - Cell transplantation

KW - Gene therapy

KW - Glaucoma

KW - Neuroprotection

KW - Neurotrophic factor

KW - Neurotrophin

KW - Slow release

UR - http://www.scopus.com/inward/record.url?scp=79955064720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955064720&partnerID=8YFLogxK

U2 - 10.1016/j.exer.2010.05.016

DO - 10.1016/j.exer.2010.05.016

M3 - Article

C2 - 20685205

AN - SCOPUS:79955064720

VL - 93

SP - 196

EP - 203

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

IS - 2

ER -